PIAZZA, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 1.036
EU - Europa 219
AS - Asia 124
AF - Africa 4
SA - Sud America 4
OC - Oceania 1
Totale 1.388
Nazione #
US - Stati Uniti d'America 1.028
CN - Cina 87
IT - Italia 71
FR - Francia 63
CZ - Repubblica Ceca 18
DE - Germania 18
FI - Finlandia 10
JP - Giappone 9
RU - Federazione Russa 9
HK - Hong Kong 8
CA - Canada 7
PL - Polonia 7
IN - India 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
SG - Singapore 5
GB - Regno Unito 4
ZA - Sudafrica 4
ES - Italia 3
BR - Brasile 2
DK - Danimarca 2
NL - Olanda 2
PT - Portogallo 2
VN - Vietnam 2
AR - Argentina 1
AU - Australia 1
CL - Cile 1
GR - Grecia 1
KR - Corea 1
LV - Lettonia 1
MX - Messico 1
RO - Romania 1
SA - Arabia Saudita 1
SE - Svezia 1
Totale 1.388
Città #
Fairfield 156
Ashburn 104
Houston 79
Seattle 69
Santa Cruz 64
Beijing 63
Woodbridge 61
Buffalo 54
Cambridge 53
Wilmington 48
Padova 37
Des Moines 22
Ann Arbor 21
Chicago 16
San Diego 10
Boardman 9
New York 9
Helsinki 8
Paris 8
Warsaw 7
Clearwater 6
Las Vegas 6
Milan 6
Phoenix 6
Redmond 6
San Francisco 6
San Jose 6
Shanghai 5
Bengaluru 4
Liberec 4
Los Angeles 4
Moscow 4
Tokyo 4
University Park 4
Büdelsdorf 3
Cedar Knolls 3
Council Bluffs 3
Frankfurt am Main 3
Henderson 3
Izano 3
Muizenberg 3
Ottawa 3
Saint Petersburg 3
Santa Clara 3
Singapore 3
Wuhan 3
Albacete 2
Atlanta 2
Brooklyn 2
Catania 2
Central 2
Cleveland Heights 2
Dallas 2
Dong Ket 2
Easton 2
Hamilton 2
Hillsboro 2
Hong Kong 2
Jacksonville 2
Lake Forest 2
Messina 2
Miami 2
Milpitas 2
Parma 2
Provo 2
Riva 2
Toulouse 2
Verona 2
Wanchai 2
Washington 2
Amsterdam 1
Aprilia 1
Auburn 1
Austin 1
Bellevue 1
Belluno 1
Boston 1
Bourne End 1
Brendola 1
Brookings 1
Chandler 1
Charlottesville 1
Chennai 1
Coimbra 1
Copenhagen 1
Créteil 1
Cuauhtemoc 1
Córdoba 1
Denia 1
Denver 1
Dulles 1
Elmhurst 1
Frankfurt Am Main 1
Genoa 1
Giarre 1
Huntsville 1
Jersey City 1
Kaiserslautern 1
Kirkland 1
Kobe 1
Totale 1.083
Nome #
STAT3 mutation impacts biological and clinical features of T-LGL leukemia, file e14fb26a-0b15-3de1-e053-1705fe0ac030 169
Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation, file e14fb26a-e48b-3de1-e053-1705fe0ac030 164
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth., file e14fb267-abd5-3de1-e053-1705fe0ac030 152
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases, file e14fb26a-54a7-3de1-e053-1705fe0ac030 138
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias, file e14fb26c-848c-3de1-e053-1705fe0ac030 128
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival, file e14fb268-c45b-3de1-e053-1705fe0ac030 126
Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma, file e14fb26c-9cf6-3de1-e053-1705fe0ac030 110
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment, file e14fb26c-b00a-3de1-e053-1705fe0ac030 82
Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research, file e14fb26d-4eff-3de1-e053-1705fe0ac030 78
Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis, file e14fb26c-81ea-3de1-e053-1705fe0ac030 74
Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3., file e14fb267-a179-3de1-e053-1705fe0ac030 29
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia, file e14fb26f-c351-3de1-e053-1705fe0ac030 18
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients, file 8bb2da37-e84f-406d-b479-2326006f3864 17
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma, file d6c9fd8e-1502-4765-9914-2c02188633d7 14
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma, file e14fb26f-94c8-3de1-e053-1705fe0ac030 14
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation, file aaf97301-4e55-41ac-9882-55c2bbada3e2 13
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients., file ccb0f900-3a13-424d-b6a4-e86c01bf471a 11
Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells, file e14fb267-aa92-3de1-e053-1705fe0ac030 11
Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes, file e14fb267-927b-3de1-e053-1705fe0ac030 10
Metabolic control of epigenetic rearrangements in B cell pathophysiology, file 115caf7f-c628-453b-b63c-b2b9458add90 9
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients., file e14fb269-5ca4-3de1-e053-1705fe0ac030 9
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies, file e14fb26e-7bdd-3de1-e053-1705fe0ac030 9
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia, file e14fb267-a4fc-3de1-e053-1705fe0ac030 8
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma, file cd5f1876-bb2b-4db5-8024-55385fcaa4bc 7
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity, file e14fb267-aa65-3de1-e053-1705fe0ac030 6
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real‐Life Campus CLL Study, file 1d074405-2d70-4d33-a979-caf9a5b10ef5 5
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas, file 475f0892-9587-4943-ada1-2a976a9cbad3 4
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome, file d7e4eb92-287a-4ae3-b665-be3507ac63fa 4
Multiple myeloma cell survival relies on high activity of protein kinase CK2, file e14fb267-879a-3de1-e053-1705fe0ac030 4
The chemokine receptor CXCR3 is expressed on malgnat B cells and mediates chemotaxis., file e14fb267-8ffd-3de1-e053-1705fe0ac030 4
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia, file e14fb270-0143-3de1-e053-1705fe0ac030 3
3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis, file e14fb267-84ef-3de1-e053-1705fe0ac030 1
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia, file e14fb268-fb50-3de1-e053-1705fe0ac030 1
Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response, file e14fb269-2342-3de1-e053-1705fe0ac030 1
Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma, file e14fb26b-3abf-3de1-e053-1705fe0ac030 1
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature, file e14fb26f-dde8-3de1-e053-1705fe0ac030 1
Totale 1.435
Categoria #
all - tutte 5.155
article - articoli 5.155
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.310


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201968 0 0 0 0 0 0 0 0 11 14 23 20
2019/2020185 15 12 9 37 16 12 13 14 21 8 19 9
2020/2021327 16 12 12 9 5 10 13 27 25 125 36 37
2021/2022294 9 14 37 19 16 12 21 25 6 12 99 24
2022/2023313 14 24 73 48 21 34 15 12 11 10 50 1
2023/2024225 3 3 10 17 13 37 39 57 46 0 0 0
Totale 1.435